Breast Lump Removal Surgery: A Guide to Different Techniques — Cost, Top Hospitals & Success Rates | MyMedicPlus

Breast lump removal surgery encompasses surgical excision of discrete breast masses — both benign and malignant — with the goal of achieving diagnostic tissue and/or complete excision with clear margins. The approach ranges from a simple excision biopsy of a benign fibroadenoma under local anaesthesia to a wide local excision (WLE) or lumpectomy for breast cancer requiring precise margin clearance, sentinel lymph node biopsy, and oncoplastic reconstruction to restore breast shape. The specific technique is determined entirely by the nature of the lump (benign vs malignant), size, location within the breast, and the patient's breast size and shape.

All palpable or imaging-detected breast lumps require triple assessment before surgery is planned: clinical examination, imaging (mammogram and/or ultrasound, MRI in selected cases), and tissue sampling (fine needle aspiration cytology or core needle biopsy). This triple assessment determines whether the lump is definitively benign (no surgery required), probably benign (close surveillance vs removal depending on patient preference and size), or suspicious/malignant (surgery required). Proceeding to surgery without adequate pre-operative assessment is inappropriate as the technique and extent of surgery differ fundamentally between benign and malignant indications.

For benign lumps — fibroadenomas, cysts, lipomas, papillomas, phyllodes tumours — surgery is indicated for increasing size, large size, patient anxiety, diagnostic uncertainty, or symptomatic lesions. For malignant lumps (breast cancer), surgery is part of a multidisciplinary treatment plan discussed at a breast multidisciplinary team (MDT) meeting involving breast surgeons, oncologists, radiologists, and pathologists. Breast-conserving surgery (lumpectomy/WLE) is offered as an alternative to mastectomy for appropriate cancers, with equivalent long-term survival outcomes when followed by adjuvant radiotherapy.

Oncoplastic breast surgery — combining standard breast cancer surgery with plastic surgery volume displacement or replacement techniques — has evolved to allow removal of proportionally larger cancers while maintaining breast aesthetics, reducing the need for mastectomy and improving cosmetic outcomes.

Surgical excision of benign breast lumps is performed for: fibroadenomas (the most common benign solid breast lump in young women — smooth, rubbery, mobile; surgery is recommended when enlarging, above 3cm, or causing patient concern); phyllodes tumours (fast-growing fibroepithelial tumours requiring wide excision as malignant variants have significant local recurrence rates); breast papillomas (intraductal growths associated with nipple discharge; surgical excision excludes underlying malignancy); lipomas and sebaceous cysts causing cosmetic concern or discomfort; and breast abscess drainage or excision in recurrent or complex cases.

For malignant breast disease, lumpectomy/WLE with sentinel lymph node biopsy (SLNB) is the preferred approach for invasive breast cancers up to 3-4cm in a breast large enough to achieve clear margins with acceptable cosmetic outcome. Ductal carcinoma in situ (DCIS) managed surgically is treated by WLE with clear margins — the extent of excision depends on the size of DCIS on imaging. Excision biopsy is used diagnostically when core biopsy results are non-diagnostic (B3 or B4 pathology — lesions of uncertain malignant potential) to obtain a more representative tissue sample.

All patients with a discrete breast lump that has been imaged and biopsied and meets surgical criteria are candidates for lump removal. For benign lumps, surgery is most appropriate when: the lump is growing rapidly; it causes pain or discomfort; the patient has ongoing anxiety despite benign biopsy results; the lump is larger than 3cm; or core biopsy is indeterminate (B3 category). Young women aged under 35 with small (under 2cm) fibroadenomas and concordant benign imaging and clinical features may be safely managed with surveillance rather than excision if they prefer.

For malignant lumps, breast-conserving surgery is appropriate when: tumour-to-breast ratio allows excision with clear margins (typically 1-2mm for invasive cancer, 2-3mm for DCIS) while preserving an acceptable cosmetic outcome; the patient does not carry BRCA1/2 mutations (where bilateral risk-reducing mastectomy may be preferred); there is no multicentric or diffuse disease on MRI; and the patient does not have a previous contraindication to radiotherapy (which is required post-lumpectomy). The treating multidisciplinary team will advise on surgical options based on tumour characteristics, imaging, and patient preferences.

Simple excision biopsy under local anaesthesia (day case) is used for superficial benign lumps — a small elliptical incision is placed along Langer's lines (natural skin tension lines) over the lump for optimal scar cosmesis, the lump is excised with a small margin of normal tissue, and the skin is closed in layers. Vacuum-assisted excision (Mammotome, EnCor) uses an ultrasound-guided minimally invasive probe to core out benign fibroadenomas through a 3-4mm nick in the skin — leaving no scar visible and providing complete histological diagnosis, ideal for fibroadenomas under 3cm.

Wide local excision (lumpectomy) for cancer requires image-guided wire or seed localisation of impalpable lesions, excision of the tumour with a margin of normal breast tissue, and intraoperative specimen radiograph to confirm the lesion is included in the excised tissue. Sentinel lymph node biopsy samples the first draining lymph node(s) using radiotracer and/or blue dye injection to stage the axilla with minimal morbidity compared to full axillary clearance. Oncoplastic techniques — lateral tissue displacement, therapeutic mammaplasty (using breast reduction pattern to simultaneously remove the cancer and reshape the breast), or round block technique — allow larger resections in cosmetically sensitive locations while maintaining breast shape and avoiding deformity.

The operating surgeon reviews the patient's complete medical history, current medications, and desired outcomes before finalising the surgical plan. Preoperative digital photography and computer simulation allow the surgeon and patient to align expectations and visualise potential results. Anaesthetic choice — general anaesthesia or intravenous sedation with local anaesthesia — is decided in consultation with the anaesthesiologist based on procedure complexity, patient health status, and patient preference. Postoperative care instructions, including wound care, activity restrictions, and follow-up scheduling, are provided in written form before surgery.

Surgical excision of a symptomatic or growing benign breast lump provides definitive tissue diagnosis, resolution of any diagnostic uncertainty, and elimination of the lump with its associated anxiety and discomfort. Vacuum-assisted excision of fibroadenomas removes the lump with minimal scarring and an outpatient procedure, offering a highly satisfactory patient experience. For most benign lump excisions, the cosmetic outcome is excellent when incisions are placed in natural skin creases.

For breast cancer, lumpectomy followed by adjuvant radiotherapy achieves equivalent 10-year and 20-year overall survival to mastectomy — established by multiple randomised trials including the landmark NSABP B-06 trial. Breast-conserving surgery preserves the natural breast mound, avoiding the physical and psychological consequences of mastectomy. Oncoplastic techniques further improve cosmetic outcomes — randomised data demonstrate higher patient satisfaction scores with oncoplastic versus conventional lumpectomy, with equivalent oncological safety. For DCIS, successful lumpectomy with clear margins reduces local recurrence risk significantly, with ten-year recurrence rates below 10% when radiotherapy is added.

Benign lump excision under local anaesthesia is very low risk. Minor complications include haematoma formation (1-2%), wound infection (1-2%), seroma (particularly for larger cavity excisions), and suboptimal scar cosmesis when incisions are not appropriately placed. The main long-term consideration is scar appearance — placed in a periareolar position or along Langer's lines, scars typically fade to near-invisibility over 12-18 months. For vacuum-assisted excision, bruising is expected and haematoma requiring drainage occurs in less than 1% of cases.

Wide local excision for cancer carries greater risks reflecting the larger tissue volume removed. Haematoma requiring reoperation (2-5%), wound infection (2-5%), positive margins requiring re-excision (15-20% of cases — managed by return to theatre for further excision or conversion to mastectomy), and seroma formation in the excision cavity are the most common complications. Sentinel lymph node biopsy has low morbidity (lymphoedema risk less than 5%), far lower than full axillary clearance (lymphoedema in 15-20%). Radiotherapy-related skin changes and long-term fibrosis of the breast tissue can affect the final cosmetic result of lumpectomy but are generally well managed with modern radiotherapy planning and techniques.

Recovery from benign lump excision under local anaesthesia is rapid — most patients return to normal activities within 24-48 hours. Mild bruising and swelling resolve within 1-2 weeks. A supportive bra is worn for 1-2 weeks. Histology results from the excised tissue are available within 1-2 weeks and are discussed at a follow-up appointment. For vacuum-assisted excision, a pressure dressing is worn for 24-48 hours; patients return to normal activity the same day.

After lumpectomy for breast cancer, hospital stay is 1-2 days (or day case for smaller procedures). Post-operative follow-up for histological margin assessment is critical — patients are informed of margins at 7-14 days. Adjuvant radiotherapy commences 4-8 weeks after surgery, followed by hormonal therapy and/or chemotherapy as indicated by tumour characteristics. Breast cancer follow-up then continues with annual mammography for at least 5 years. Oncoplastic results are reviewed at 3 months and 12 months. Patients with BRCA mutations are offered enhanced screening or risk-reducing surgery discussion at their genetics centre.

In the USA, benign breast lump excision costs USD 3,000-7,000 depending on anaesthesia type, facility, and complexity. Wide local excision with sentinel node biopsy for breast cancer in the USA costs USD 15,000-30,000 including operating theatre, anaesthesia, pathology, and surgeon fees — these costs are typically covered by insurance for cancer diagnoses. In the UK, NHS covers all medically indicated breast lump surgery without cost to the patient; private surgery costs GBP 3,000-8,000.

For patients seeking breast surgery abroad, medical tourism to India, Thailand, Turkey, or Eastern Europe offers significant savings for benign lump excision (USD 800-2,500) and even for breast cancer surgery at internationally accredited oncology centres (USD 5,000-12,000 for WLE with SLNB). Oncological surgical care at JCI-accredited cancer centres in India (Tata Memorial, Apollo Cancer Centres) and Thailand (Bumrungrad International) is comparable to Western standards, with multidisciplinary teams and full adjuvant therapy capabilities. Patients with cancer diagnoses seeking care abroad should ensure pathology samples can be sent internationally for second opinion review.

For benign fibroadenomas, non-surgical management by ultrasound surveillance is appropriate for small (under 2cm), non-growing lesions with definitively benign biopsies. High-intensity focused ultrasound (HIFU) ablation and cryoablation are emerging non-invasive techniques for fibroadenoma destruction under imaging guidance — these are offered at some specialist centres as alternatives to excision, avoiding any scar. For breast cancer, mastectomy (removal of the entire breast) remains an alternative to lumpectomy — offering lower local recurrence risk but equivalent survival, at the cost of breast loss and greater psychological impact. Mastectomy is chosen when lumpectomy cannot achieve clear margins, when the patient strongly prefers it, or in BRCA carriers for whom risk-reducing mastectomy is appropriate. Neoadjuvant chemotherapy given before surgery can shrink larger tumours to allow breast-conserving surgery in cases that would otherwise require mastectomy.